Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast


Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Latest news

11/24/2022 Pharmaceutical Drug Production in Russia (October 2022)

In January–October 2022, Russian manufacturers produced 579.5 billion rubles’ worth of ready-made drugs (manufacturer’s prices, VAT included), up 18.5% from the same period in 2021. As usual, the high inflation rate played a significant role here, especially since it has been 10% or higher since March. In physical terms, the production volume was 3.44 billion packages, up 2.9% from January–October 2021. If calculated in minimum dosage units (MDU), the volume was 65.4 billion MDUs, up 2.1% from the same period last year.

11/12/2022 Ranking of Russian Pharmaceutical Distributors (Q1–Q3 2022)

Market Shares of Seven Major Pharmaceutical Distributors Decline in Q1–Q3 2022

11/11/2022 RNC Pharma: Market Shares of Seven Major Pharmaceutical Distributors Decline in Q1–Q3 2022

The number of factors influencing the Russian pharmaceutical market may have reached a historic high this year, which is why partial mobilization was hardly surprising. The way it affected the Russian economy is worth describing as vividly as possible. First, a significant part of consumers was lost, including not only the mobilized conscripts, but also those “tourists” who fled Russia to its neighboring states, with solvent consumers among them. Second, for a relatively short period of time, the pharmaceutical market saw a “militarization” of demand, which included the need to provide conscripts with drugs and medical devices used in warfare, as well as general panic moods stimulating the demand for certain drugs.

10/31/2022 Database Update: Audit of Veterinary Drug Retail Sales in Russia (September and Q1–Q3 2022)

In Q1–Q3 2022, the sales of veterinary drugs in the Russian retail market were 16.8 billion RUB (retail prices, VAT included), down 3.6% from Q1–Q3 2021. Even the actively growing e-commerce with its growth rates of 67% could not save the situation. In physical terms, the sales were 107.5 million minimum dosage units (MDU), down 20%. The online sales went up 33%, while the offline sales fell 21%.

10/28/2022 Import of Veterinary Drugs and Feed Supplements to Russia (September and Q1–Q3 2022)

From January to September 2022, Russia imported 28.1 billion rubles’ worth of veterinary drugs (customs clearance and VAT included), 5.1% up from the same period last year. In physical terms, the growth rate was 7.6%, with 24.4 million packages imported. As for feed supplements, the growth rates in both monetary and physical terms are negative: –2.3% in rubles and –12.1% in tons. The import of feed supplements in January–September was 110,300 tons worth around 31.8 billion rubles.

All news [354]

Our competences

RNC Pharma is focused on providing information about development trends of Russian pharmaceutical market infrastructure component. Our experts also provide services on strategic marketing, such as forecasting, business planning, etc.